Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	1.90T
Revenue (ttm)	1.28T
Net Income (ttm)	59.42B
Shares Out	67.71M
EPS (ttm)	877.52
PE Ratio	31.91
Forward PE	n/a
Dividend	200.00 (0.72%)
Ex-Dividend Date	Dec 27, 2024

Volume	29,366
Average Volume	71,449
Open	27,850
Previous Close	27,950
Day's Range	27,700 - 28,150
52-Week Range	24,250 - 52,500
Beta	0.96
RSI	53.75
Earnings Date	Apr 30, 2025

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 444
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2024, Hanmi Science's revenue was 1.28 trillion, an increase of 2.85% compared to the previous year's 1.25 trillion. Earnings were 59.42 billion, a decrease of -48.38%.